A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT05735184
Trial Phases:	Phase I	Protocol IDs:	KO-MEN-007 (primary) NCI-2023-04854
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Kura Oncology Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT05735184

Summary

This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic
activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and
7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.

Treatment Sites in Georgia

Georgia Cancer Center at Augusta University
1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.